Allogeneic adipose
for the therapies of tomorrow.

About Britecyte View products

650+ patients ● Patent-protected technology

Pioneering the next generation of human tissue therapies.

Britecyte was born in 2020 out of a quiet laboratory, a global shutdown, and an unfinished journey.

When the COVID-19 pandemic forced the world to a standstill, Founder and Chief Scientific Officer Dr. Alla Danilkovitch saw an unexpected opportunity. Renting a single laboratory bench, she channeled the global silence into absolute, singular focus. Her mission? To solve complex, unmet medical needs through biocompatible, allogeneic human cell and tissue-based therapies.

By 2022, that intense isolation and time spent in the lab yielded a breakthrough: the successful development of Britecyte’s proprietary allogeneic adipose technology. With initial funding secured, Samson Tom joined as President and CEO to help build a team and transform this scientific breakthrough into a commercial reality.

But Britecyte’s roots run much deeper than 2020. For decades, the promise of regenerative medicine has captivated scientists. Alla, Sam, and early colleagues spent years at Osiris Therapeutics, helping develop and launch first-in-class products like Osteocel®, Cartiform®, Grafix®, and Stravix®. Their team also led the development of Prochymal® (later Ryoncil®), the world’s first approved stem cell therapy.

Today, Britecyte carries that 30-year legacy forward—focused on restoring and repairing adipose tissue where it is lost or dysfunctional.

2020—Company founded by Dr. Alla Danilkovitch
2022—MSCRF grant; allogeneic adipose technology validated
2023–2024—Liposana and Lipoderma commercial launches
Today—650+ patients restored • Foundational patent • IND-cleared knee OA trial

A breakthrough in adipose science.

For decades, adipose tissue restoration has relied on patients serving as their own donor. Britecyte's proprietary technology changes that by enabling the use of donor-derived (allogeneic) adipose tissue while preserving its native architecture.

  1. Qualified donor adipose

    Human adipose tissue is recovered from qualified donors under established tissue-banking standards. This provides the biological starting material—native fat cells with its extracellular structure intact—before any Britecyte processing begins.

  2. Immunogenicity resolution

    Britecyte's proprietary, patent-protected process addresses the immunogenicity that has historically restricted adipose to autologous use. The tissue is processed to enable allogeneic transplantation while preserving native architecture—not reduced to a synthetic gel or cross-linked filler.

  3. Native allograft

    The result is a ready to use human adipose allograft developed without synthetic agents, cross-linkers, or foreign scaffolds. Lipoderma and Liposana maintain like-for-like tissue structure—biocompatible, off-the-shelf products physicians can implant directly. Lipoderma is available in 1.5 cc and 10 cc vials; Liposana in 1.5 cc vials. The formula preserves intact adipocytes and extracellular matrix in a 90:10 ratio—unmatched in the industry.

  4. Patient restoration

    Experienced physicians place the allograft where adipose has been lost or is deficient—restoring the fat that supports healthy skin (Lipoderma) or providing structural cushioning for tissue repair in areas of adipose deficits (Liposana). Over 650 patients have received Britecyte allografts to date.

Native adipose technologies for distinct clinical needs.

Built on the same proprietary adipose platform, our products leverage the unique biology of human adipose to support multiple clinical applications.

Aesthetic restoration

Designed to restore volume by replacing what has been lost. Lipoderma is a native human adipose allograft that supports natural tissue restoration through like-for-like replacement of adipose tissue.

  • Facial and body applications
  • Select provider network
  • 1.5 cc and 10 cc formats
Learn about Lipoderma →
Tissue repair

Designed to restore the natural cushioning provided by healthy adipose tissue. Liposana is a native human adipose allograft that replaces lost adipose tissue to support structural comfort and function.

  • Fat pad restoration
  • Supports natural cushioning
  • Available in 1.5 cc format
Learn about Liposana →

An expanding therapeutic pipeline.

Investigational programs in knee osteoarthritis and metabolic disease—built on the same adipose platform.

Explore the pipeline →

Latest from Britecyte.

View all news

Meet the team.

Samson Tom
Samson Tom, PhD, MBA President and CEO, Co-Founder

Dr. Tom became President and CEO of Britecyte in June 2022. He brings more than 25 years of experience developing and commercializing advanced biologics, devices, and tissue-based products—including as President and CEO of Osiris Therapeutics through its acquisition by Smith+Nephew.

Alla Danilkovitch
Alla Danilkovitch, PhD Founder and Chief Scientific Officer

Dr. Danilkovitch founded Britecyte in 2020 and leads its scientific vision in regenerative medicine. At Osiris Therapeutics she helped develop Prochymal®, BIO4™, Cartiform®, Grafix®, and Stravix™—with 30+ years of experience, 55 patents, and 60 publications across academia, government, and industry.

Molly Saunders
Molly Saunders Vice President, Sales and Marketing

Molly Saunders joined Britecyte in January 2024. Previously Senior Manager of Clinical Operations at Osiris Therapeutics, she managed multi-center tissue-based studies and co-authored publications supporting market access and reimbursement before consulting in life sciences at Alvarez & Marsal.

Lisa Rodemann
Lisa Rodemann Director, Customer Experience

Lisa Rodemann joined Britecyte in January 2026. She spent 25 years at Osiris Therapeutics and Smith+Nephew across Human Resources, Clinical Programs, Marketing, and project management—including Advanced Wound Care and white-glove support for key accounts during the pandemic.

Peter Friedli
Peter Friedli Chairman and Co-Founder

Peter Friedli has led Swiss venture capital firm Friedli Corporate Finance AG since 1986, investing in more than 170 high-tech and biotechnology companies. He co-founded and chaired Osiris Therapeutics and was its major shareholder.

Get in touch.

Britecyte, Inc.
Frederick, MD
brighterlives@britecyte.com